Conclusion:
Hemolytic anemia is a significant complication associated with the use of primaquine. Therefore, screening for G6PD deficiency is essential before initiating primaquine therapy, and heightened vigilance is necessary even when G6PD levels are within the normal range on screening. There is a need for clearer instructions on how to detect signs of hemolysis.